Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NPSP NPS Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (58)	12/29/1999 5:40:00 PM
From: WTDEC	Read Replies (2) \| Respond to of 363

biowa, Nice news release..>) Wednesday December 29, 4:47 pm Eastern Time Company Press Release SOURCE: NPS Pharmaceuticals, Inc. Core Receptor Technology Patents Awarded to NPS Pharmaceuticals SALT LAKE CITY, Dec. 29 /PRNewswire/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP - news; Toronto: NX - news) announced today the issuance and notices of allowance of 14 U.S. patents and patent applications received from the United States Patent and Trademark Office (USPTO). Together, this group of patents defines a cohesive and large body of intellectual property focused on the calcium receptor (CaR) and the related family of metabotropic glutamate receptors (mGluRs). This core technology, in turn, is the basis for several major NPS programs, partnered and proprietary. The partnered programs include hyperparathyroidism (HPT) and osteoporosis, while the proprietary programs address disorders such as pain, epilepsy, anxiety, psoriasis, and diabetes. (Photo: newscom.com ) <SNIP> biz.yahoo.com Enjoy! Walter